Mills, Anthony <br/><br/>
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients:  randomized, open-label pilot study.  [electronic resource] 

 -  Journal of acquired immune deficiency syndromes (1999)  Feb 2013 
 - 164-70 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1944-7884 
<br/><br/><label>Standard No.: </label>10.1097/QAI.0b013e31827b51b5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adolescent<br/>Adult<br/>Aged<br/>Anti-HIV Agents--therapeutic use<br/>Atazanavir Sulfate<br/>CCR5 Receptor Antagonists<br/>CD4 Lymphocyte Count<br/>Cyclohexanes--adverse effects<br/>Deoxycytidine--analogs & derivatives<br/>Drug Therapy, Combination--adverse effects<br/>Emtricitabine<br/>Female<br/>HIV Fusion Inhibitors--adverse effects<br/>HIV Infections--drug therapy<br/>HIV-1<br/>Humans<br/>Male<br/>Maraviroc<br/>Middle Aged<br/>Oligopeptides--therapeutic use<br/>Organophosphonates--therapeutic use<br/>Pilot Projects<br/>Pyridines--therapeutic use<br/>RNA, Viral--blood<br/>Ritonavir--therapeutic use<br/>Tenofovir<br/>Triazoles--adverse effects<br/>Viral Load<br/>Young Adult